Back
Compare AU
Compare IHD vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the iShares S&P/ASX Div Opportunities Esg Screened ETF (IHD) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IHD | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 95 | 83 |
Median incremental investment | $820.34 | $674.27 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,866.76 | $2,220.00 |
Average age group | > 35 | > 35 |
Key Summary
IHD | CURE | |
|---|---|---|
Strategy | IHD.AX was created on 2010-12-06 by iShares. The fund's investment portfolio concentrates primarily on high dividend yield equity. The ETF currently has 400.2m in AUM and 51 holdings. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of 50 ASX listed stocks that offer high dividend yields while meeting diversification, profitability and tradability requirements as well as being screened for sustainability considerations | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | BHP GROUP LTD (10.93 %) RIO TINTO LTD (10.39 %) ANZ GROUP HOLDINGS LTD (9.29 %) | Moderna Inc (2.20 %) Twist Bioscience Corp (1.84 %) Natera Inc (1.80 %) |
Top 3 industries | Financials (44.69 %) Materials (25.27 %) Industrials (15.28 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Australia (99.86 %) New Zealand (0.14 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0.23 % | 0.45 % |
Key Summary
IHD | CURE | |
|---|---|---|
Issuer | iShares | Global X |
Tracking index | S&P/ASX Dividend Opportunities Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.23 % | 0.45 % |
Price | $16.52 | $74.00 |
Size | $402.928 million | $47.072 million |
10Y return | 25.63 % | N/A |
Annual distribution yield (5Y) | 5.38 % | 0.03 % |
Market | ASX | ASX |
First listed date | 09/12/2010 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IHD | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 95 | 83 |
Median incremental investment | $820.34 | $674.27 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,866.76 | $2,220.00 |
Average age group | > 35 | > 35 |
Pros and Cons
IHD | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
IHD | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |